GSK plc (NYSE:GSK) Holdings Lifted by Quintet Private Bank Europe S.A.

Quintet Private Bank Europe S.A. grew its holdings in shares of GSK plc (NYSE:GSK) by 14.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,700 shares of the pharmaceutical company’s stock after purchasing an additional 2,260 shares during the period. Quintet Private Bank Europe S.A.’s holdings in GSK were worth $724,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Primecap Management Co. CA grew its holdings in shares of GSK by 13.9% in the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock worth $558,689,000 after acquiring an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD boosted its holdings in shares of GSK by 37.8% in the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after buying an additional 1,512,442 shares during the period. Equity Investment Corp raised its holdings in shares of GSK by 1.0% during the second quarter. Equity Investment Corp now owns 3,433,202 shares of the pharmaceutical company’s stock valued at $132,178,000 after acquiring an additional 34,631 shares during the period. Renaissance Technologies LLC lifted its position in shares of GSK by 30.9% in the 2nd quarter. Renaissance Technologies LLC now owns 2,347,993 shares of the pharmaceutical company’s stock valued at $90,398,000 after acquiring an additional 554,600 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in GSK by 33.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock worth $86,875,000 after purchasing an additional 569,614 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on GSK. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

GSK Stock Up 0.8 %

Shares of NYSE GSK traded up $0.31 during trading hours on Monday, hitting $37.19. The stock had a trading volume of 528,838 shares, compared to its average volume of 3,842,413. The firm’s 50-day moving average price is $40.66 and its two-hundred day moving average price is $41.04. GSK plc has a 52 week low of $33.89 and a 52 week high of $45.92. The company has a market capitalization of $77.08 billion, a P/E ratio of 24.13, a P/E/G ratio of 1.45 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.54 and a current ratio of 0.81.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.22%. GSK’s dividend payout ratio is 100.00%.

Insider Activity

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.